Conversely, the SFRP family of proteins, notably SFRP4, SFRP2, and SFRP1, serve as antagonists to Wnt signalling and have demonstrated efficacy in diminishing CSC traits such as drug resistance, stemness, metastasis, and proliferation across various cancer types. This evidence concerns the gene SFRP2 and cancer.